Table 3.
Comparison between CTRCD and non-CTRCD.
| CTRCD (n = 20) | Non-CTRCD (n = 75) | p Value | |
|---|---|---|---|
| Cardiovascular risk factors | |||
| Hypertension, n (%) | 8 (40.0) | 11 (15.3) | 0.029 |
| Diabetes, n (%) | 3 (15.0) | 8 (10.2) | 0.703 |
| Dyslipidemia, n (%) | 3 (15.0) | 1 (1.2) | 0.034 |
| Coronary artery disease, n (%) | 1 (5.0) | 1 (1.2) | 0.397 |
| Atrial fibrillation or atrial flutter, n (%) | 2 (10.0) | 4 (5.1) | 0.611 |
| Oncologic risk factor | |||
| Adriamycin cumulative dose, mg/m2 | 430 ± 133 | 394 ± 113 | 0.084 |
| Concomitant use of ICI | 8 (40.0) | 14 (18.7) | 0.044 |
| Baseline LV systolic function | |||
| LVEF, % | 67 ± 6 | 66 ± 6 | 0.408 |
| LVGLS, % | −18.0 ± 1.9 | −17.4 ± 3.2 | 0.296 |